86-21-64556180
cpd-service@caerulumpharma.com

Nrf2

nke

Kpọtụrụ anyị

Ajuju

Akụkọ kacha ọhụrụ

  • AstraZeneca na-enweta nkwalite nchịkwa maka ọgwụ oncology

    AstraZeneca na-enweta nkwalite nchịkwa maka ...

    AstraZeneca nwetara nkwalite okpukpu abụọ maka pọtụfoliyo oncology ya na Tuesday, mgbe ndị na-ahụ maka US na European nabatara ntinye iwu maka ọgwụ ya, nzọụkwụ mbụ iji nweta nkwado maka ọgwụ ndị a. ...

  • Usoro 7 kachasị na nyocha ọgwụ na 2018

    Usoro 7 kacha elu na nyocha ọgwụ m...

    N'ịbụ ndị nọ n'okpuru nrụgide na-arịwanye elu mgbe niile ịsọ mpi na gburugburu ebe obibi akụ na ụba na nkà na ụzụ siri ike, ụlọ ọrụ ọgwụ na biotech ga-anọgide na-emepe emepe na mmemme R&D ha iji nọgide na-aga n'ihu ...

  • ARS-1620: Onye mmechi ọhụrụ na-ekwe nkwa maka ọrịa cancer KRAS-mutant

    ARS-1620: ihe mgbochi ọhụrụ na-ekwe nkwa maka K…

    Dị ka otu nnyocha e bipụtara na Cell si kwuo, ndị nchọpụta ewepụtala ihe mgbochi kpọmkwem maka KRASG12C nke a na-akpọ ARS-1602 nke na-eme ka ụbụrụ tumor regression na ụmụ oke. "Ọmụmụ ihe a na-enye na vivo ihe akaebe na mutant KRAS nwere ike ịbụ ...

  • AstraZeneca na-enweta nkwalite nchịkwa maka ọgwụ oncology

    AstraZeneca na-enweta nkwalite nchịkwa maka ...

    AstraZeneca nwetara nkwalite okpukpu abụọ maka pọtụfoliyo oncology ya na Tuesday, mgbe ndị na-ahụ maka US na European nabatara ntinye iwu maka ọgwụ ya, nzọụkwụ mbụ iji nweta nkwado maka ọgwụ ndị a. ...

  • Usoro 7 kachasị na nyocha ọgwụ na 2018

    Usoro 7 kacha elu na nyocha ọgwụ m...

    N'ịbụ ndị nọ n'okpuru nrụgide na-arịwanye elu mgbe niile ịsọ mpi na gburugburu ebe obibi akụ na ụba na nkà na ụzụ siri ike, ụlọ ọrụ ọgwụ na biotech ga-anọgide na-emepe emepe na mmemme R&D ha iji nọgide na-aga n'ihu ...

    • prev
    next
© Nwebiisinka - 2015-2022: Ikike niile echekwabara.
Mkparịta ụka WhatsApp n'ịntanetị!
Close
PreviousNext
PreviousMaximize
Next